Blau症候群の疾患特異的iPS細胞モデルにおいて、マクロファージがIFN-γ依存性に炎症反応を引き起こす by TAKADA, Sanami & 高田, 紗奈美
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Pluripotent stem cell models of Blau syndrome reveal  
an IFN-g–dependent inflammatory response in macrophages 
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Abstract 
Background: Blau syndrome, or early-onset sarcoidosis, is a juvenile-onset systemic 
granulomatosis associated with a mutation in nucleotide-binding oligomerization domain 
2 (NOD2). The underlying mechanisms of Blau syndrome leading to autoinflammation 
are still unclear, and there is currently no effective specific treatment for Blau syndrome. 
 
Objectives: To elucidate the mechanisms of autoinflammation in Blau syndrome, we 
sought to clarify the relation between disease associated-mutant NOD2 and the 
inflammatory response in human samples. 
 
Methods: Blau syndrome-specific induced pluripotent stem cells (iPSCs) lines were 
established. To precisely evaluate the in vitro phenotype of iPSC-derived cells, the 
disease-associated NOD2 mutation of iPSCs was corrected using a CRISPR-Cas9 system. 
We also introduced the same NOD2 mutation into a control iPSC line. These isogenic 
iPSCs were then differentiated into monocytic cell lineages, and the status of NF-κB 
pathway and proinflammatory cytokine secretion were investigated. 
 
Results: IFN-γ acted as a priming signal through the up-regulation of NOD2. In iPSC-
derived macrophages with mutant NOD2, IFN-γ treatment induced ligand-independent, 
NF-κB activation and proinflammatory cytokine production. RNA-seq analysis revealed 
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distinct transcriptional profiles of mutant macrophages both before and after IFN-γ 
treatment. Patient-derived macrophages demonstrated a similar IFN-γ-dependent 
inflammatory response. 
  
Conclusions: Our data support the significance of ligand-independent autoinflammation 
in the pathophysiology of Blau syndrome. Our comprehensive isogenic disease-specific 
iPSC panel provides a useful platform for probing therapeutic and diagnostic clues for 
the treatment of Blau syndrome patients. 
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INTRODUCTION 
Blau syndrome (OMIM: #186580), or early-onset sarcoidosis, is a hereditary juvenile-
onset systemic granulomatosis1. Clinical symptoms appear before the age of 4 years and 
mainly affect the skin, joints, and eyes2. The symptoms are progressive and cause severe 
complications such as joint destruction and blindness3. The pathological findings of 
affected lesions include granuloma formation mainly composed of macrophages with 
other cells such as multinuclear giant cells and lymphocytes4, which is associated with 
local chronic inflammation. Although TNF-α antagonists are partially effective for 
controlling some symptoms, such as arthritis5, 6, there is no specific curative treatment at 
present for patients with Blau syndrome7. 
Heterozygous mutations of nucleotide-binding oligomerization domain 2 (NOD2), 
or caspase recruitment domain-containing protein 15 (CARD15), were identified as 
responsible for the onset of Blau syndrome8. NOD2 protein is an intracellular pathogen 
recognition receptor, the ligand of which is known as muramyl dipeptide (MDP), found 
in bacterial cell walls9, 10. Upon recognition of the ligand, NOD2 leads to the activation 
of the nuclear factor kappa B (NF-κB) pathway, thereby causing the up-regulation of 
proinflammatory cytokines and chemokines9-13. However, the details regarding the 
molecular mechanisms by which Blau syndrome-associated mutant NOD2 leads to 
autoinflammation and granuloma formation are still unclear.  
Because of several controversial reports, whether Blau syndrome-associated NOD2 
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mutations are gain-of-function or loss-of-function mutations is still argued. For example, 
in a model of HEK293 cells, ligand-independent auto-activation of NF-κB reporter 
activity was observed on the overexpression of Blau syndrome-associated mutant NOD2, 
indicating that Blau syndrome is caused by gain-of-function mutations of NOD214. 
Conversely, a knock-in mouse model described a reduction in the levels of 
proinflammatory cytokines responsive to NF-κB pathway upon stimulation with MDP, 
showing the possibility of loss-of-function15. However, since the mouse model did not 
show any phenotype of Blau syndrome in vivo, we recognized the need to investigate 
specific perturbations that abstract the unique function of mutant NOD2 using human 
samples.   
Although NOD2 is mainly expressed in hematopoietic lineage cells, especially in 
monocytic cells13, the excessive production of proinflammatory cytokines or chemokines 
was not observed in peripheral blood mononuclear cells (PBMCs) of Blau syndrome 
patients16, 17 Whereas other autoinflammatory syndrome patients usually suffer from 
periodic proinflammatory attacks, the clinical course of Blau syndrome is usually slow 
and progressive without specific episodes of febrile attacks, which hampers the evaluation 
of the disease activity of Blau syndrome. A lack of clinical parameters associated with 
disease activity makes it difficult to elucidate the mechanisms of this disease.  
Substantial evidence supports a potential role of IFN-γ in the pathophysiology of 
Blau syndrome. Prominent IFN-γ expression was found in and around the granulomas of 
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biopsy specimens from Blau syndrome patients, indicating its commitment in the 
progression of granuloma4. IFN-γ is also described as a downstream mediator of NOD2-
driven inflammation leading to uveitis18. In some patients, BCG vaccination was 
sometimes associated with the onset of this disease19, 20, showing the possibility that a 
BCG-associated immune response triggers a NOD2-dependent inflammatory pathway, 
which leads to flare up of Blau syndrome symptoms. Since IFN-γ is a major cytokine 
associated with BCG-mediated immune responses21, it may be involved in provoking a 
NOD2-mediate inflammatory response. Furthermore, IFN-γ, TNF-α, and other Toll-like 
receptor ligands act as priming signals to up-regulate NOD2 expression22-24. However, 
currently, there are no reports describing the direct effect of IFN-γ on Blau syndrome-
associated immune cells. 
Here we established Blau syndrome-patient-specific human induced pluripotent 
stem cell (iPSC) lines to develop in vitro disease models for elucidating the mechanisms 
of autoinflammation in Blau syndrome25. The iPSC model is free from the influence of 
the in vivo cellular environment, such as medication or endogenous cytokines. Taking 
advantage of the nature of human pluripotent stem cells, in that their genome sequence 
can be edited relatively easily using the CRISPR-Cas9 genome editing system26, 27, we 
established isogenic iPSC pairs sharing the same genomic backgrounds but different 
NOD2 genotypes. In the present study, we corrected the NOD2 R334W mutation, which 
is one of the most common variants of Blau syndrome28, in the Blau patient derived iPSCs. 
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In a similar manner, we introduced the NOD2 R334W mutation into an iPSC clone from 
a healthy donor. Using macrophages derived from these isogenic iPSC panels, we 
investigated the relationship between Blau syndrome associated-mutant NOD2 and the 
proinflammatory response. 
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METHODS 
Ethical matters 
This study was approved by the Ethics Committee of Kyoto University, and informed 
consent was obtained from the patient’s guardians in accordance with the Declaration of 
Helsinki. Written informed consent was obtained from all patients. The peripheral blood 
mononuclear cells for iPSC generation were obtained from two independent Blau 
syndrome patients (Blau1, CIRA00232; and Blau2, CIRA00233).  
 
Patients 
Two Japanese boys with the NOD2-R334W-mutation diagnosed as Blau syndrome as 
previously described29, 30 were recruited to establish iPSCs. The patients were brothers. 
Their father with the same NOD2-mutation was also diagnosed as Blau syndrome as 
previously described20, 30, 31. Each of the two patients had the similar clinical episode that 
erythematous papules appeared after BCG vaccination at 6 months of age. Thereafter one 
of the patients (Blau1) developed skin rash and arthritis without uveitis, then he had 
received treatment with non-steroidal anti-inflammatory drugs and methotrexate. Another 
patient (Blau2) developed skin rash without arthritis or uveitis, then he had not received 
any specific medication. PBMCs were obtained from another unrelated patient who had 
the same NOD2-R334W mutation to obtain monocyte-derived macrophages. 
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Primers 
The primers used in this study are listed in Table E1. 
 
Control iPSC lines 
The human iPSC line 201B725 was kindly provided by Dr. Shinya Yamanaka (Kyoto 
University, Kyoto, Japan).  
 
Establishment and maintenance of iPSCs 
iPSCs were generated from blood cells as described previously32, 33. Briefly, blood cells 
were isolated from peripheral blood using a BD Vacutainer (BD BioSciences, San Jose, 
CA) in accordance with the manufacturer’s instructions. The PBMCs were cultured in 
StemSpan-ACF medium (StemCell Technologies, Vancouver, Canada) containing SCF 
(100 ng/mL), TPO (100 ng/mL), Flt-ligand (100 ng/mL), IL-6 (50 ng/mL), and IL-3 (10 
ng/mL) for 5 days before transfection. SCF, TPO, Flt-ligand, IL-6, and IL-3 were 
purchased from R&D Systems (Minneapolis, MN). Episomal plasmids (3 µg) mixed with 
pCE-hOCT3/4, pCE-hSK, pCE-hUL, pCE-mp53DD, and pCXB-EBNA1 were 
transfected into 1-2 × 106 cultured PBMCs using a Nucleofector 2b device with an Amaxa 
Human CD34 cell Nucleofector kit. The electroporated cells were plated onto tissue 
culture plates coated with the Laminin511-E8 fragment iMatrix-511 (Nippi, Tokyo, 
Japan) containing StemSpan-ACF medium with the same cytokines as described above. 
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The culture medium was gradually changed to StemFit AK03 medium (Ajinomoto, 
Tokyo, Japan). Two to three weeks after the transduction, the individual colonies were 
isolated and expanded. The iPSCs were cultured on LN511E8-coated tissue culture plates 
with StemFit AK03 medium at 37 °C, with 5% CO2 and 21% O2, and passaged via 
dissociation into single cells using TrypLE Select (Life Technologies, Gaithersburg, MD) 
as described previously32. 
 
Characterization of established iPSCs 
Chromosomal G-banding analyses were performed at the Nihon Gene Research 
Laboratory in Miyagi, Japan. For the teratoma formation assay, approximately 2 × 106 
cells were injected subcutaneously into the dorsal flank of immunocompromised 
NOD/scid/ccnull mice (Central Institute for Experimental Animals, Kawasaki, Japan). 
Masses were excised 9-14 weeks after injection and fixed with 4% paraformaldehyde in 
phosphate-buffered saline (-) (PBS [-]). Paraffin-embedded tissues were sliced and 
stained with hematoxylin and eosin. The slides were examined using the BIOREVO BZ-
9000 microscope (Keyence, Osaka, Japan). A PlanApo 10×/0.45 objective (Nikon, Tokyo, 
Japan) and the BZ-II Viewer software program (KEYENCE) were used for image 
acquisition. 
 
Flow cytometry 
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Surface markers on hematopoietic cells were evaluated with a MACSQuant Analyzer 
(Miltenyi Biotec, Bergisch Gladbach, Germany). The primary antibodies for the analysis 
were as follows: CD11b-FITC (Beckman Coulter, Brea, CA), CD45-FITC (BD 
Pharmingen, San Diego, CA), CD34-PE (Beckman Coulter), CD86-PE (BD Pharmingen), 
CD11c-APC (BD Pharmingen), and CD14-APC (Beckman Coulter). The dead cells were 
excluded by DAPI (Sigma-Aldrich, St Louis, MO) staining. The data analyses were 
performed using the FlowJo software program (TreeStar, Ashland, OR).  
 
May-Giemsa staining 
Cells were seeded onto glass slides by PLATINUMPRO (Matsunami, Osaka, Japan) and 
stained with May-Grunwald and Giemsa staining solution (Merck Millipore, Darmstadt, 
Germany) in accordance with the manufacturer’s instructions. The slides were examined 
using a BIOREVO BZ-9000 (Keyence). A PlanApo 40×/0.95 objective (Nikon) and the 
BZ-II Viewer software program (Keyence) were used for image acquisition. 
 
Hematopoietic cell differentiation 
Hematopoietic cell differentiation was performed in accordance with previously 
described protocols with some modifications34, 35. Briefly, 4 × 102-1.6 × 103 
undifferentiated iPSCs were first disseminated onto a 6-well tissue culture dish coated 
with growth factor-reduced Matrigel in mTeSR1 medium. When individual colonies grew 
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to approximately 500 µm in diameter, differentiation was started by adding BMP4 (80 
ng/mL, R&D systems). The cells were cultured under 37 °C, with 5% CO2 and 5% O2 
during differentiation. On day 2, the medium was replaced by Essential 6 (Life 
Technology) containing VEGF (80 ng/mL), basic FGF (50 ng/mL), SCF (50 ng/mL), and 
SB431542 (2 µM). On day 4, the medium was replaced by Stemline 2 (Sigma-Aldrich) 
containing SCF (50 ng/mL), TPO (5 ng/mL), IL-3 (50 ng/mL), M-CSF (50 ng/mL), and 
Flt-3 ligand (50 ng/mL) for monocytic cell differentiation. On day 12, the cytokines were 
switched to the combination of M-CSF (50 ng/mL), Flt-3 ligand (50 ng/mL), and GM-
CSF (25 ng/mL). BMP4, VEGF, SCF, TPO, IL-3, M-CSF, GM-CSF, and Flt-ligand were 
purchased from R&D Systems. Basic FGF, CHIR99021, was purchased from Wako Pure 
Chemical Industries (Osaka, Japan). SB431542 was purchased from Merck Millipore. 
 
Sanger sequencing 
Genomic DNA was extracted from the cells using the AllPrep DNA/RNA Mini Kit 
(Qiagen, Hilden, Germany) or PureLink Genomic DNA Kits (Invitrogen, Carlsbad, CA) 
and subjected to PCR amplification with primers for NOD2 genotyping (Table E1). After 
treatment with USB ExoSAP-IT (Affymetrix, Santa Clara, CA), the PCR products were 
used for Sanger sequencing. Sequencing was performed with the BigDye® Terminator 
v3.1 Cycle Sequencing Kit (Applied Biosystems, Carlsbad, CA), and the subsequent 
products were purified using the BigDye XTerminator® Purification Kit (Applied 
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Biosystems). The 3500xL sequencer (Applied Biosystems) was used for analyses. Data 
were analyzed using the CodonCode Aligner software program (CodonCode Corporation, 
Centerville, MA). 
 
Generation of immortalized proliferating myeloid cell lines (iPS-MLs) 
iPS-MLs were established as previously described36. In brief, lentiviral constructs 
encoding BMI1, cMYC, and MDM2 in the CSII-EF-RfA vector were kindly provided by 
Drs. Satoru Senju (Kumamoto University, Kumamoto, Japan) and Hiroyuki Miyoshi 
(RIKEN Bio Resource Center, Tsukuba, Japan). Floating hematopoietic cells 
differentiated into the monocytic lineage from iPSCs were collected on days 15 to 18. 
The cells were transfected with the lentiviral vectors and subsequently cultured in 
StemPro-34 serum-free medium containing 2 mM L-glutamine in the presence of M-CSF 
(50 ng/mL). For macrophage differentiation, the culture conditions were changed to 
RPMI-1640 medium (Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS) 
and M-CSF (100 ng/mL) for 7 to 9 days. For polarization of macrophages, IL-4 (20 
ng/mL) or IFN-γ (20 ng/mL) was added for last 24 hours. We then collected the adherent 
macrophages by treating them with Accumax (Innovative Cell Technologies, San Diego, 
CA) and used the collected cells for subsequent experiments. 
 
Generation of corrected or Knocked-in iPSC clones 
 15 
We corrected the mutant NOD2 gene using the CRISPR-Cas9 system. The guide RNA 
(gRNA) sequence was designed on the coding sequence of NOD2 in intron 3 
(CCTTCAGTTATGTCAGCGTCCCC). gRNA vector and Cas9 vector were purchased 
from Takara Bio (Shiga, Japan). Clones maintained under feeder-free conditions were 
dissociated into a single cell. Vectors expressing gRNA and Cas9 were then introduced 
using a NEPA21 electroporator (Nepagene, Chiba, Japan). Two days after transfection, 
cells were incubated with puromycin (0.5-1 µg/mL) for 24-48 hours or neomycin (50 
µg/mL) for 1 week. Surviving colonies were picked up 1 week after the start of selection, 
passaged and expanded several times, and frozen. The DNA was extracted from the cells 
and genotyped by Sanger sequencing as described above. Vectors expressing Cre 
recombinase were then introduced by HuGENE HD Transfection Reagent (Promega, 
Madison, WI) to excise the loxP-flanked drug selection cassette. For the construction of 
the C-terminal 3×FLAG sequence knocking-in allele, the gRNA sequence was designed 
on the coding sequence of NOD2 in exon 12 (CTTGCTTTGAAGTCTCCGGGAGG). 
Vectors were transfected, and cells were cultured as described above.  
 
Quantitative PCR (qPCR) 
RNA samples were prepared using AllPrep DNA/RNA Mini Kit (Qiagen) or RNeasy 
Mini Kit (Qiagen) and subjected to reverse transcription using a PrimeScript RT Master 
Mix (Takara Bio). All procedures were performed in accordance with the manufacturer’s 
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instructions. qPCR was performed on the StepOnePlus™ Real-Time PCR System 
(Applied Biosystems). For the detection of transgenes, DNA was subjected to qPCR, and 
SYBR Premix ExTaqII (Takara Bio) was used for detection. Relative quantification 
values are shown. For the quantification of the expression of PSC-associated genes (Fig. 
E1C), qPCR was performed with cDNA and the Fast Advanced Master Mix (Applied 
Biosystems). The data were processed using the ΔΔCt method, and the relative quantities 
(RQ) to the control 201B7 line are shown. The primer sequences are shown in Table E1. 
 
Immunoblotting 
Cell lysates were lysed for 30 min on ice in RIPA buffer (Wako Pure Chemical Industries) 
plus proteinase inhibitor cocktail (Nacalai Tesque, Kyoto, Japan). After being centrifuged 
at 15,000g for 20 min at 4 °C, the supernatants were collected, and dithiothreitol was 
added. The lysates were incubated at 95 °C for 5 minutes. The proteins were then 
separated by sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
and transferred to a PVDF membrane. The membranes were blocked with 3% nonfat milk 
in Tris-buffered saline (TBS) plus 0.1% Tween20. Immunoblotting was performed with 
FLAG M2 mouse monoclonal antibody (1:1000; Sigma-Aldrich) and HRP-conjugated 
anti-mouse IgG antibody (1:3000; Santa Cruz Biotechnology, Santa Cruz, CA) and 
detected using a LAS4000 (Fujifilm, Tokyo, Japan). 
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NF-κB Dual Luciferase assay 
The iPS-MLs were transfected with pGreenFire NF-κB transcription reporter lenti vector 
(System Biosciences, Mountain View, CA), inserted with the Renilla gene under the CMV 
promoter as an internal control. The iPS-MLs were differentiated into macrophages as 
described above. The cells were cultured with or without 50 ng/mL of IFN-γ (R&D 
System) for 24 hours, with the addition of 10 µg/mL of MDP (Sigma-Aldrich) for the last 
6 hours. The NF-κB activity was then measured using the Dual-Luciferase Reporter 
Assay System (Promega). 
 
Immunofluorescence 
The macrophages were seeded into multi-well glass-bottom dish (Matsunami) and 
cultured with or without 50 ng/mL of IFN-γ for 24 hours, with the addition of 10 µg/mL 
of MDP for the last 60 minutes. The cells were then fixed with 4% paraformaldehyde in 
PBS (-) for 30 minutes. Permeabilization and blocking were performed with blocking 
buffer (Blocking One [Nacalai Tesque] with 0.1% Tween20 [Santa Cruz Biotechnology]) 
for 30 minutes. The samples were incubated with anti-NF-κB p65 rabbit monoclonal 
antibody (1:400; Cell Signaling Technologies, Danvers, MA) in blocking buffer overnight 
at 4 °C, and subsequently incubated with Alexa Fluor 488 goat anti-mouse IgG (1:1000; 
Cell Signaling Technologies) for 30 minutes. The nuclei were stained with DAPI (1:100) 
in PBS (-). The cells were visualized using a FluoVIew10i confocal microscope 
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(Olympus, Tokyo, Japan) and analyzed using Image J software (NIH, Bethesda, MD). 
 
Cytokine assay 
The concentrations of cytokines in the culture supernatants were measured using 
LEGENDplexTM Multi-Analyte Flow Assay Kits (BioLegend, San Diego, CA) in 
accordance with the manufacturer’s instructions. Quantification was done with a 
MACSQuant Analyzer (Miltenyi Biotec). The iPS-MLs were differentiated into 
macrophages as described above. For stimulation, the cells were treated with IFN-γ (50 
ng/mL) for 24 hours, and MDP (10 µg/mL) was added to the medium for the last 6 hours 
when indicated. 
 
Isolation of PBMCs and macrophage differentiation 
After receiving informed consent, peripheral blood was drawn from a patient and two 
healthy volunteers. PBMCs were isolated by Lymphoprep (STEMCELL Technologies). 
CD14-positive monocytic cells were sorted using EasySep Human CD14 Positive 
Selection Kit (STEMCELL Technologies). The cells were differentiated into 
macrophages as described above, and the differentiated macrophages were then subjected 
to an analysis. 
 
ChIP-qPCR  
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After stimulation, the cells were cross-linked in 1% formaldehyde for 10 minutes at room 
temperature. The nuclear lysates were sonicated using a sonicator (Misonix, Farmingdale, 
NY). After being centrifuged at 15,000g for 30 min at 4 °C, the supernatants were 
collected. The clarified lysates were divided in half and treated overnight at 4 °C with 10 
µg of anti-NF-κB p65 (C-20) rabbit polyclonal antibody (Santa Cruz Biotechnology) or 
Rabbit IgG polyclonal-Isotype control (Abcam, Cambridge, UK) pre-incubated with 
Dynabeads M-280 Sheep anti-Rabbit IgG (Thermo Fisher Scientific, Waltham, MA). The 
protein-DNA complexes were captured on a magnet and eluted with TE buffer containing 
1% SDS at 65 °C. Following cross-link reversal and purification with MinElute PCR 
Purification Kit (Qiagen), quantitative PCR was performed as described above. The 
primer sequences are described in Table E1. 
 
Cell viability assay 
The cell viability was measured using a CountessTM Automated Cell Counter (Invitrogen, 
Carlsbad, CA). For stimulation, the cells were treated with IFN-γ (50 ng/mL) for 24 hours, 
and MDP (10 µg/mL) was added to the medium for the last 6 hours when indicated. 
 
RNA-sequence (RNA-seq) and data normalization 
RNA-seq analysis was performed at Kazusa DNA Institute as previously described37. 
RNA-seq libraries were prepared using a SureSelect Strand Specific RNA Library 
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Preparation kit (Agilent Technologies, Santa Clara, CA). Sequencing was performed on 
an Illumina HiSeq1500 using a HiSeq Rapid SBS kit v2 (Illumina, San Diego, CA) in a 
50-base single-end mode. The mRNA profiles were compiled using the Cufflinks (ver. 
2.2.1) software program and expressed as fragments per kilobase of exon model per 
million mapped fragments (FPKM). For the analysis, the data sets filtered by the criterion 
requiring FPKM >0 in at least one sample were first subjected to variance-stabilizing 
transformation and interquartile range filtering. Then, upper-quartile (UQ) normalization 
followed by remove unwanted variations (RUV) normalization regarding each three line 
of treated and untreated samples as a replicated group (RUVs), modeling k = 1 factors of 
unwanted variation was performed to remove unwanted variations38, 39. UQ and RUVs 
normalization was conducted using the open-source R package Deseq2 and RUVSeq, the 
source code of which is freely available through the Bioconductor Project. 
 
Gene Set Enrichment Analysis (GSEA) 
GSEA (http://software.broadinstitute.org/gsea/index.jsp) was used to estimate the 
biological signatures. Normalized data sets were applied for each analysis using 
Molecular Signatures Database v5.1 (Hallmark gene sets, size-filters set at 15-500). 
 
GSE accession numbers 
RNA-seq datasets were deposited in the GEO database and can be accessed with the GEO 
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accession number GSE98454. 
 
Statistics 
All of the statistical analyses were performed using the Excel, R and Prism software 
programs. The values are presented as the mean ± S.E.M or S.D., as indicated in the 
Figure Legends. The statistical analysis was done using either Student’s t-test or the 
Wilcoxon rank sum test. 
 
RESULTS 
Generation of Blau syndrome patient-specific iPSCs and associated isogenic iPSC 
panels 
We first established and characterized multiple iPSC lines from 2 Blau syndrome patients 
with a heterozygous R334W (1000C>T) NOD2 mutation (referred to as Blau1A-1F and 
Blau2A-2F, see Table E2). Blau-iPSCs were confirmed to carry the corresponding 
heterozygous point mutation on exon 4 of the NOD2 gene, showed typical pluripotent 
stem cell like-morphology, maintained a normal karyotype, and expressed comparable 
levels of pluripotency-associated genes (NANOG and OCT3/4) to a control iPSC line 
(Table E2). We selected representative iPSC clones from both patients (Blau1E and 
Blau2B) and named them Blau1-R334W (Blau1E) and Blau2-R334W (Blau2B). The data 
of these representative clones for the evaluation of iPSC-quality are shown in Figure 
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E1A-E1C. The pluripotency of Blau-iPSC clones including Blau1-R334W and Blau2-
R334W was confirmed using a teratoma formation assay (Table E2 and Figure E1D).  
To understand the pathophysiology derived from Blau syndrome-associated mutant 
NOD2 in a strictly controlled isogenic background, we next corrected the mutation in the 
Blau1-R334W and Blau2-R334W iPSC clones using a CRISPR-Cas9 mediated 
targeting26, 27 (referred to as Blau1-corrected and Blau2-corrected, respectively, Figure 
1A). In the corrected clone (Blau1-corrected and Blau2-corrected), the inserted allele was 
validated by genomic PCR (Figure 1B and E1E), and the T to C correction of NOD2 on 
exon 4 was confirmed via the Sanger sequencing (Figure 1C and E1F). In a similar 
manner, we also introduced a heterozygous NOD2-R334W mutation into control 201B7-
iPSCs (referred to as 201B7-WT for parental control 201B7, and 201B7-R334W for 
mutated 201B7, Figure E1G-E1I). To investigate the expression of endogenous NOD2, 
we generated 201B7-WT iPSCs with 3× FLAG-tagged NOD2 in the C-terminal using the 
CRISPR-Cas9 system (referred to as 201B7-WT-NOD2-FLAG, Figure E1J and E1K).  
 
Differentiation of iPSCs into a monocytic lineage 
Since monocytic lineage cells, especially macrophages, express NOD2, produce 
inflammatory cytokines robustly, and play a pivotal role in the formation of granulomas, 
we first differentiated iPSCs into a monocytic lineage using a previously reported 
protocol35. We tracked the expression of NOD2 mRNA during the differentiation and 
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found the monocytic lineage cells derived from iPSCs expressed NOD2 on day 12 of 
differentiation (Figure 1D). The iPSC-derived monocytes were then further differentiated 
into macrophages and stimulated with IFN-γ or IL-4 in order to elicit polarization into 
M1 or M2 macrophages35. Of note, the iPSCs-derived macrophages treated by IFN-γ 
showed especially high expression of NOD2, as previously described22-24 (Figure 1D). 
IFN-γ treatment up-regulated the expression of NOD2 protein (Figure 1E), thus 
indicating a priming role of IFN-γ in the NOD2-NF-κB signaling pathway. 
Given these observations, we next investigated the in vitro function of NOD2 in 
iPSC-derived macrophages. One of the obstacles facing disease iPSC studies is that 
directed differentiation from iPSCs is often time- and labor-intensive, whereas the 
functional analysis often shows high variance. To overcome these issues and stably obtain 
a scalable number of mature monocytic cells from engineered iPSC clones, immortalized 
proliferating myeloid cell lines (iPS-MLs) were established from iPSC-derived 
monocytes by introducing three transgenes: cMYC, BMI1, and MDM236. The established 
iPS-MLs showed a monocytic appearance (Figure E2A) and expressed CD33 but only 
expressed CD14 slightly (Figure E2B), indicating their characteristics of immature 
monoblast-like status. When the iPS-MLs were differentiated into macrophages (iPS-
ML-derived macrophages, referred to as iPS-MPs), the expression of macrophage surface 
cell markers CD14, CD68, and CD11b were up-regulated (Figure E2C). These iPS-MPs 
demonstrated an adherent cell appearance, and IFN-γ treatment gave them an M1-
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macrophage-like elongated, tightly attached appearance (Figure E2D). 
 
NF-κB is similarly activated in iPS-MPs with wild-type and mutant NOD2 
The activation of NOD2 by its ligands such as MDP is involved in the immune response 
induced by NF-κB activation9, 11, 13. To investigate the activation of NF-κB in cells with 
wild-type NOD2 and NOD2 mutations, we next tracked the nuclear translocation of NF-
κB p65, a subunit of NF-κB transcription complex, as a parameter of NF-κB activation 
(Figure 2A-2C). In untreated iPS-MPs, NF-κB p65 localized mostly in the cytosol. Upon 
stimulation with MDP, NF-κB p65 remained in the cytosol for a shorter time course (1 to 
5 minutes after stimulation) and translocated into the nucleus after 30 minutes to 1 hour. 
With MDP treatment after 6 hours, NF-κB p65 was returned into the cytosol. Overall, the 
response of NF-κB to MDP stimulation was similar in cells with wild-type and mutant 
NOD2. 
 
IFN-γ induces ligand-independent NF-κB activation on NOD2-mutated iPS-MPs 
To investigate the role of mutant NOD2 on immune response, we first investigated the 
NF-κB transcription activity in iPS-MPs using a luciferase reporter system. Interestingly, 
IFN-γ priming significantly increased the luciferase activity in mutant iPS-MPs without 
secondary stimulation by MDP (Figure 3A). The degree of NF-κB activation in mutant 
iPS-MPs by IFN-γ increased in a dose- and time-dependent manner (Figure E3A and 
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E3B). Both wild-type and mutant iPS-MPs were able to react to MDP at comparable 
levels of NF-κB activation (Figure 3A). The time course of the degree of NF-κB 
activation in both the wild-type and mutant iPS-MPs by MDP peaked at 4 hours after 
stimulation and then started to decrease, which was earlier than observed with IFN-γ 
(Figure E3C). The activation of NF-κB in cells treated with IFN-γ and MDP, was higher 
than that in cells that were only treated with MDP in both wild-type and mutant iPS-MPs 
(Figure 3A), suggesting a priming role of IFN-γ in the NOD2-NF-κB signaling pathway. 
The activation of NF-κB signaling with lipopolysaccharide (LPS), which is mainly 
mediated by the Toll-like receptor signaling pathway40, was not significantly different 
between wild-type and mutant clones (Figure E3A).  
To evaluate the NF-κB activation in each cell, we next investigated the nuclear 
translocation of NF-κB p65. Some of the IFN-γ-primed cells in the mutant clone showed 
NF-κB p65 nuclear translocation without MDP (Figure 3B), suggesting a ligand-
independent activation state. The immunofluorescent density of the nuclear-translocated 
NF-κB p65 in mutant iPS-MPs was significantly increased compared to that in wild-type 
cells (Figure 3C). In contrast, untreated cells demonstrated no obvious spontaneous 
nuclear translocation of NF-κB in either wild-type or mutant iPS-MPs (Figure 3B and 
3C). MDP treatment increased NF-κB activity at comparable levels between wild-type 
and mutant iPS-MPs (Figure 3B and 3C), as mentioned above in Figure 2. 
Overall, IFN-γ priming induces the ligand-independent activation of the NF-κB 
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pathway in mutant iPS-MPs, which may associate with an overproduction of 
proinflammatory cytokines.  
 
IFN-γ induces proinflammatory cytokine production on NOD2-mutated iPS-MPs by 
increasing the binding of NF-κB p65 to their promoter regions 
To evaluate the consequence of NF-κB activation, we next measured the production of 
proinflammatory cytokines and chemokines (Figure 4A-4C). When untreated, the 
production of proinflammatory cytokines from both wild-type and mutant clones was 
negligible. IFN-γ priming significantly increased the production of common NF-κB-
responsive cytokines such as IL-6, IL-8, and TNF-α in mutant iPS-MPs without 
secondary MDP stimulation, consistent with the status of NF-κB pathway. No marked 
differences in cell viability were noted with each stimulation, regardless of the genotype 
or type of stimulation (Figure E4), excluding the effect of cell death on the cytokine 
profiles. On the other hand, despite the comparable levels of NF-κB activity, the 
production of these cytokines with MDP in mutant iPS-MPs was significantly lower than 
those from wild-type iPS-MPs. No significant secretion of other cytokines such as IL-1β, 
IL-10, or IL-12p70 was observed in either wild-type or mutant iPS-MPs under these 
conditions (Figure E3C-E3E).  
To confirm that the increased cytokine production on IFN-γ-primed mutant iPS-
MPs was associated with the NF-κB activation, a chromatin immunoprecipitation (ChIP) 
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assay with NF-κB p65 protein was performed. IFN-γ priming induced the ligand-
independent recruitment of NF-κB p65 to the promoter specific regions of IL-6 and IL-8 
in mutant iPS-MPs (Figure 4D and 4E). We referenced the NF-κB activation, 
proinflammatory cytokine production, and binding to the promoters using another 
isogenic pair of iPS-MPs to evaluate the consistency (Blau1-corrected and Blau1-R334W, 
Figure E5A-E5F) and confirmed that all isogenic pairs including Blau1 showed 
consistent results regarding the response to IFN-γ. Overall, our data indicate that the 
production of proinflammatory cytokines by IFN-γ-primed iPS-MPs with mutant NOD2 
is at least partially induced through the ligand-independent activation of the NF-κB 
pathway.  
 
RNA-seq analysis reveals the involvement of inflammatory response in IFN-γ-primed 
iPS-MPs with a Blau syndrome-associated NOD2 mutation 
The above data revealed the relevance of the IFN-γ-induced NF-κB activation and 
proinflammatory cytokine production, indicating difference in the biological status 
between mutant and wild-type untreated iPS-MPs in evoking an inflammatory response. 
To clarify the involvement of this response, we performed an RNA-sequencing (RNA-
seq) analysis to evaluate the changes in the global transcriptional profiles of iPS-MPs. To 
assess the global effects of genotype and treatment on the transcriptome of iPS-MPs, we 
first performed a principal component analysis (PCA) plot from the normalized gene 
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counts of samples with each treatment. The transcriptome clustered predominantly by 
treatment, while the inter-clonal difference was minimal (Figure 5A, for the process of 
normalization, see Figure E6A-E6C). A hierarchical clustering analysis also 
demonstrated that untreated and IFN-γ-treated samples grouped into distinct clusters 
(Figure 5B). In order to extract the differently regulated pathways between mutant and 
wild-type iPS-MPs, we next performed a gene set enrichment analysis (GSEA)41. We 
confirmed that IFN-γ treatment significantly enriched IFN-γ response pathway in all 
clones compared to the untreated state (Figure E6D and E7E). In mutant iPS-MPs upon 
IFN-γ treatment, several inflammatory pathways, such as 
“TNFA_SIGNALING_VIA_NFKB” and “INFLAMMATORY_RESPONSE” (False 
discovery rate (FDR) <0.25) were significantly enriched when compared to wild-type 
iPS-MPs (Figure 5C). Interestingly, we noticed that similar inflammatory pathways were 
already up-regulated in mutant iPS-MPs, even in the untreated state (Figure 5D). These 
data support the idea that untreated mutant iPS-MPs are already in a distinct biological 
state for evoking an inflammatory response, which is maintained even after IFN-γ priming, 
leading to an enhanced inflammatory response, such as via proinflammatory cytokine 
production.  
 
Blau syndrome patient’s primary macrophages primed by IFN-γ caused ligand-
independent NF-κB activation and proinflammatory cytokine production 
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Although the iPSC-derived isogenic monocytic cell line pairs enabled us to precisely 
evaluate the in vitro phenotype, there remains a possibility that the long-term in vitro 
culture and introduction of transgenes might alter the cellular phenotype. To exclude this 
possibility, we investigated whether or not the in vitro phenotypes could be recapitulated 
with primary monocyte-derived macrophages (Mo-MPs). For this, Mo-MPs were 
obtained from the PBMCs of a Blau syndrome patient with a NOD2-R334W mutation. 
IFN-γ treatment up-regulated the endogenous expression of NOD2 in Mo-MPs from the 
control (Figure 6A). Both the control- and patient-derived Mo-MPs demonstrated no 
obvious spontaneous nuclear translocation of NF-κB when untreated (Figure 6B and 6C). 
Similar to the observation with iPS-MPs, some of the IFN-γ-primed Mo-MPs from the 
patient showed NF-κB p65 nuclear translocation without MDP, and the degree of NF-κB 
p65 nuclear translocation was significantly larger in the patient-derived Mo-MPs than in 
those of the control (Figure 6B and 6C). MDP stimulation promoted the nuclear 
translocation of NF-κB p65 in both the control and patient, but the degree was smaller in 
the patient’s Mo-MPs than in those of the control.  
We then evaluated production of proinflammatory cytokines from Mo-MPs. IFN-γ 
priming significantly increased the production of IL-6, IL-8, and TNF-α from the patient-
derived Mo-MPs in a ligand-independent manner (Figure 6D-6F). Collectively, IFN-γ 
treatment activated NF-κB pathway and induced production of proinflammatory 
cytokines from patient-derived macrophages. These data were compatible with those 
 30 
from iPS-MPs, confirming the validity and usefulness of our iPSC-based modeling. 
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DISCUSSION 
In this study, we demonstrated that IFN-γ-primed human macrophages with Blau 
syndrome-associated mutant NOD2 cause the ligand-independent activation of NF-κB 
transcription and production of proinflammatory cytokines such as IL-6 and IL-8. One of 
the main roadblocks to studying Blau syndrome-associated NOD2 mutants has been the 
lack of a proinflammatory response in mutant cells in vitro despite autoinflammatory 
symptoms in vivo. Since both patient-derived cells and a knock-in mouse model also 
showed reduced proinflammatory responses, the argument remains as to whether the Blau 
syndrome-associated NOD2 mutations are gain-of-function or loss-of-function. In the 
present study, we identified IFN-γ as a specific stimulant inducing a pro-inflammatory 
response in both iPSC- and patient-derived primary macrophages. Of note, humans with 
complete IFN-γ receptor deficiency, whether IFN-γR1 or IFN-γR2, do not display any 
mature granuloma42, indicating the essential role of IFN-γ in the formation of granulomas. 
Our data provide important insights into the role of NOD2 in IFN-γ-dependent granuloma 
formation. Although the involvement of IFN-γ signaling has been implicated in the 
pathology of BS, there have been no reports proving the direct effect of IFN-γ on the 
function of mutant NOD2. Our findings revealed a previously undefined pathway for 
activating NOD2-mutated macrophages.  
RNA-seq data indicated that untreated macrophages with mutant NOD2 are already 
in a primed biological state to evoke an inflammatory response. While untreated 
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macrophages did not activate the NF-κB pathway due to a shortage of auto-activated 
mutant NOD2 protein, the up-regulation of mutant NOD2 expression by IFN-γ may cause 
auto-activation of NOD2, leading to subsequent NF-κB activation. However, since the 
relationship between IFN-γ-induced prionflammatory cytokine production and 
granuloma formation is still largely unknown, further studies will be required to gain a 
comprehensive understanding of the pathophysiology of Blau syndrome.  
A response to MDP subsequently reduced the level of proinflammatory cytokine 
production in mutant iPS-MPs, which is consistent with the previous findings in the 
mouse model15 and in the patients’ PBMCs17. While MDP treatment did not lead to 
reduced cytokine production in the primary Mo-MPs in our study, one of the fundamental 
problems in the functional analysis of human primary cells is the large degree of variance, 
even among healthy controls, which is shown in Figure 6D-6F. Cell-derived iPSCs share 
the same genomic backgrounds as primary blood cells, but the NOD2 genotypes differ 
between isogenic pairs, which enables us to exclude any interpersonal variance. The loss 
of response to MDP in cytokine production may be associated with the pathogenesis of 
Blau syndrome, because granulomas are sometimes caused by the inability to eliminate 
foreign bodies and pathogens43. In contrast to the findings of the cytokine-production 
assay, MDP stimulation activated NF-κB pathway in both mutant and wild-type clones, 
and tended to enhance the recruitment of the NF-κB p65 subunit to promoter regions of 
IL-6 and IL-8 (see Figure 4D and 4E). Although the underlying mechanism for this 
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paradoxical response remain to be elucidated, our data indicate the possible existence of 
an alternative suppressive pathway activated by mutant NOD2 or another pathway 
through MDP for producing proinflammatory cytokines independent of NOD2. 
Based on our observation from iPS-MPs and patient-derived MoMPs, blocking the 
IFN-γ signaling in Blau syndrome patients can be a potential treatment for managing 
chronic inflammation. For example, the Janus kinase inhibitors tofacitinib, baricitinib, 
and ruxolitinib are already clinically available. However, before this concept can be 
applied in a clinical setting, a number of issues remain to be solved. First, we do not have 
direct evidence to prove that the IFN-γ pathway is activated in Blau syndrome patients. 
For this, further studies investigating the primary samples of patients, including blood 
and pathological specimens, will be required to confirm the up-regulation of IFN-γ 
signatures. Second, since there are other priming signals, such as TNF-α, LPS, and other 
Toll-like receptor ligands, known to up-regulate the expression of NOD222-24, IFN-γ-
dependent priming of macrophages may not be the principal condition for evoking 
autoinflammation. In the current study, we did not evaluate the effects of these signals 
because of the technical difficulty for distinguishing the Toll-like receptor- or TNF 
receptor-dependent NF-κB activation from the NOD2-dependent one. However, IFN-γ 
usually does not transduce signals activating the NF-κB pathway, enabling us to 
investigate the role of IFN-γ as a priming signal. Third, we must consider other effects of 
IFN-γ associated with a substantial immune response and other signal pathways. To avoid 
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these issues, we must suppress the specific pathways induced by mutant NOD2 when 
applying this therapy in treatments. 
In conclusion, by investigating the functions of macrophages under controlled 
conditions using a comprehensive isogenic iPSC panel with a Blau syndrome-associated 
NOD2 mutation, we were able to perform strictly controlled cellular assays and found 
that IFN-γ provokes a series of aberrant inflammatory responses in mutant macrophages. 
Since we mainly focused on the NOD2-dependent NF-κB-pathway activation using 
macrophages in this study, further studies exploring alternative NOD2-dependent 
pathways or with other cell types are required to clarify the comprehensive 
pathophysiology of Blau syndrome. Phenotypes related to genotypes other than R334W 
should be also evaluated. Through the Blau syndrome study, we expect that our iPSC 
model will also provide an opportunity for elucidating the previously unknown 
mechanisms of granuloma formation in other diseases. 
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FIGURE LEGENDS 
Figure 1. Establishment of an isogenic iPSC panel with Blau syndrome-specific 
clones. A, A schematic illustration of the stepwise gene correction of the NOD2 R334W 
mutation using the CRISPR-Cas9 system. The arrows indicate the PCR primers used in 
(B, E1E). B, The validation of the corrected allele by genomic PCR. C, Representative 
chromatogram of Sanger sequencing of NOD2. D, The quantitative RT-PCR validation of 
NOD2 expression during differentiation into macrophages derived from iPSCs. Data are 
presented as the means ± S.D (n = 3). E, Western blotting of NOD2-FLAG protein in iPS-
MPs treated with IFN-γ (50 ng/mL) for 24 hours. Data are from at least 3 independent 
experiments. 
 
Figure 2. The time course of the nuclear translocation of NF-κB p65 in iPS-MPs by 
MDP. A, The representative confocal images of immunofluorescence staining of NF-κB 
p65 (green). The cells were treated with MDP (10 µg/mL) for the indicated times. The 
cells were stained with DAPI for the visualization of the nucleus (blue). Scale bars = 40 
µm. B-C, Quantitation of the nuclear translocation of NF-κB p65 by immunofluorescence 
staining. The mean fluorescence intensity of NF-κB p65 (green) merged with the nucleus 
(blue) in each cell was plotted. The bars indicate the mean ± S.D (n = 36-80). Data are 
from at least 3 independent experiments. 
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Figure 3. IFN-γ-dependent NF-κB activation on iPS-MPs with Blau syndrome-
associated mutant NOD2. A, NF-κB activation as evaluated using a NF-κB luciferase 
reporter system. Cells were treated with IFN-γ (50 ng/mL) for 24 hours, with the addition 
of MDP (10 µg/mL) for the last 6 hours. The relative fold-change from the untreated 
condition (set as 1) is shown. Data are presented as the means ± S.E.M (n = 3). *p < 0.05. 
An unpaired t-test was used for the statistical analysis. B-C, Evaluation of the nuclear 
translocation of NF-κB p65. (B), The representative confocal images of 
immunofluorescence staining of NF-κB p65 (green). The cells were treated with IFN-γ 
(50 ng/mL) for 24 hours, with the addition of MDP (10 µg/mL) for the last 60 minutes. 
The cells were stained with DAPI for the visualization of the nucleus (blue). Scale bars = 
40 µm. (C), Quantitation of the nuclear translocation of NF-κB p65 at the single-cell level. 
The mean fluorescence intensity of NF-κB p65 (green) merged with the nucleus (blue) in 
each cell was plotted. The bars indicate the means ± S.D (n = 20-35). NS, not significant; 
**p < 0.01. A Wilcoxon rank sum test was used for the statistical analysis. Data are from 
at least 3 independent experiments. 
 
Figure 4. IFN-γ induces proinflammatory cytokine production on NOD2-mutated 
iPS-MPs by increasing the binding of NF-κB p65 to their promoter regions. A-C, 
Secretion of proinflammatory cytokines IL-6 (A), IL-8 (B), and TNF-α (C). The cells were 
treated with IFN-γ (50 ng/mL) for 24 hours, with the addition of MDP (10 µg/mL) for the 
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last 6 hours. Data are presented as the means ± S.E.M (n = 3). NS, not significant; *p < 
0.05; **p < 0.01. An unpaired t-test was used for the statistical analysis. D-E, 
Quantitative PCR analysis of chromatin immunoprecipitation samples (ChIP-qPCR) 
using anti-NF-κB p65 antibody. The binding to the promoter region of IL-6 (D) and IL-8 
(E) was evaluated. The cells were treated with IFN-γ (50 ng/mL) for 24 hours, with the 
addition of MDP (10 µg/mL) for the last 60 minutes. Data are presented as the means ± 
S.D (n = 3). NS, not significant; *p < 0.05; **p < 0.01. An unpaired t-test was used for 
the statistical analysis. Data are from at least 3 independent experiments. 
 
Figure 5. RNA-seq analysis of iPS-MPs. A, Principal component analysis based on the 
normalized RNA-seq data. Each symbol indicates each clone with each treatment. B, 
Hierarchical clustering and heat map of the normalized RNA-seq data. The peak transcript 
level is magenta, and the trough is cyan. C-D, Gene set enrichment analysis (GSEA). The 
gene sets of significantly (FDR<0.25) enriched in mutant iPS-MPs with each treatment 
(treated with IFN-γ (C), or untreated (D)) in Hallmarks are shown (size-filtered by 15-
500). 
 
Figure 6. IFN-γ-dependent NF-κB activation and proinflammatory cytokine 
production in patient-derived Mo-MPs. A, Quantitative RT-PCR validation of NOD2 
expression in control Mo-MPs. The cells were treated with IFN-γ (50 ng/mL) for 24 hours. 
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The relative fold-change from the untreated condition (set as 1) is shown. Data are 
presented as the means ± S.D (n = 3). B-C, Evaluation of the nuclear translocation of NF-
κB p65. (B), The representative confocal images of immunofluorescence staining of NF-
κB p65 (green). The cells were treated with IFN-γ (50 ng/mL) for 24 hours, with the 
addition of MDP (10 µg/mL) for the last 60 minutes. The cells were stained with DAPI 
for visualization of the nucleus (blue). Scale bars = 40 µm. (C), Quantitation of the nuclear 
translocation of NF-κB p65 at the single-cell level. The mean fluorescence intensity of 
NF-κB p65 (green) merged with nucleus (blue) in each cell was plotted. The bars indicate 
the means ± S.D (n = 18-34). NS, not significant; *p < 0.05; **p < 0.01. A Wilcoxon 
rank sum test was used for the statistical analysis. D-F, Secretion of proinflammatory 
cytokines IL-6 (D), IL-8 (E), and TNF-α (F). The cells were treated with IFN-γ (50 
ng/mL) for 24 hours, with the addition of MDP (10 µg/mL) for the last 6 hours. Data are 
presented as the means ± S.E.M (n = 3). NS, not significant; *p < 0.05. An unpaired t-
test was used for the statistical analysis. Data are from 2 independent experiments. 
 
Figure E1. Characterization of iPSCs. A, Morphology of iPSCs. Scale bars = 100 µm. 
B, Karyotype analysis of representative clones. C, Quantitative RT-PCR validation of the 
expression of pluripotent stem cell-associated genes NANOG and OCT4. D, 
Representative images of the teratoma formation assay. The arrow indicates melanin. 
Scale bars = 100 µm. E, The validation of the corrected allele by genomic PCR in Blau1-
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R334W iPSCs. F, Representative chromatogram of Sanger sequencing of NOD2. G, A 
schematic illustration of the stepwise gene knock-in of NOD2 R334W mutation into 
control 201B7 iPSC clones using the CRISPR-Cas9 system. The arrows indicate the PCR 
primers used in (H). H, Validation of the knocked-in allele by genomic PCR. I, 
Representative chromatogram of Sanger sequencing of NOD2. J. A scheme for 
introducing the 3 × FLAG tag into the C-terminus of NOD2 using the CRISPR-Cas9 
system. The arrows indicate PCR primers used in (E). K, The validation of the knocked-
in allele by genomic PCR. 
 
Figure E2. Characterization of iPS-MLs and iPS-MPs. A, The representative May-
Giemsa images of iPS-MLs. Scale bars = 40 µm. B, Flow cytometric analysis of iPS-
MLs. The white area shows the isotype control. C, Flow cytometric analysis of 
untreated iPS-MPs. The white area shows the isotype control. D, The representative 
May-Giemsa images of iPS-ML-macrophages. Scale bars = 40 µm. The cells were 
treated with IFN-γ (50 ng/mL) for 24 hours. 
 
Figure E3. Response of iPS-MPs to IFN-γ. A-B, Dose- and time-dependence of NF-
κB activation by IFN-γ evaluated using a NF-κB luciferase reporter system. (A), iPS-
ML-macrophages were treated with the indicated dose of IFN-γ for 24 hours or LPS 
(100 ng/mL) for 6 hours (n = 3). (B), iPS-MPs were treated with IFN-γ (50 ng/mL) for 
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the indicated time periods. MDP (10 µg/mL) was added for the last 60 minutes, when 
indicated (n = 3). The relative fold-change from the untreated condition (set as 1) is 
shown. C, Time course of NF-κB activation by MDP evaluated using a NF-κB 
luciferase reporter system. iPS-MPs were treated with MDP (10 µg/mL) for the 
indicated time periods (n = 3). The relative fold-change from the untreated condition 
(set as 1) is shown. D-F, Secretion of cytokines IL-1β (D), IL-10 (E), and IL-12p70 (F). 
The cells were treated with IFN-γ (50 ng/mL) for 24 hours, with the addition of MDP 
(10 µg/mL) for the last 6 hours (n = 3). A-F, Data are presented as the means ± S.E.M. 
Data are from at least 3 independent experiments. 
 
Figure E4. Cell viability of iPS-MPs. The cells were treated with IFN-γ (50 ng/mL) 
for 24 hours, with the addition of MDP (10 µg/mL) for the last 6 hours (n = 3). Data are 
presented as the means ± S.D. Data are from at least 3 independent experiments. 
 
Figure E5. Ligand-independent NF-κB activation and proinflammatory cytokine 
production on iPS-MPs with Blau syndrome-associated mutant NOD2. A, NF-κB 
activation as evaluated using a NF-κB luciferase reporter system. Cells were treated 
with IFN-γ (50 ng/mL) for 24 hours, with the addition of MDP (10 µg/mL) for the last 6 
hours. The relative fold-change from the untreated condition (set as 1) is shown. Data 
are presented as the means ± S.E.M (n = 3). B-D, Secretion of proinflammatory 
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cytokines IL-6 (B), IL-8 (C), and TNF-α (D). The cells were treated with IFN-γ (50 
ng/mL) for 24 hours, with the addition of MDP (10 µg/mL) for the last 6 hours. Data are 
presented as the means ± S.E.M (n = 3). E-F, Quantitative PCR analysis of chromatin 
immunoprecipitation samples (ChIP-qPCR) using anti-NF-κB p65 antibody. The 
binding to the promoter region of IL-6 (E) and IL-8 (F) was evaluated. The cells were 
treated with IFN-γ (50 ng/mL) for 24 hours, with the addition of MDP (10 µg/mL) for 
the last 60 minutes. Data are presented as the means ± S.D (n = 3). A-F, *p < 0.05; **p 
< 0.01. An unpaired t-test was used for the statistical analysis. Data are from at least 3 
independent experiments. 
 
Figure E6. RNA-seq analysis of iPS-MPs. A, Principal component analysis based on 
the RNA-seq data before normalization. Each symbol indicates each clone with each 
treatment. B-C, Box plots of relative log expression for unnormalized (B) and normalized 
(C) counts. The bottom and top of the box indicate the first and third quartiles, 
respectively; the inside line indicates the median. D-E, Gene set enrichment analysis 
(GSEA). The gene sets of significantly (FDR<0.25) enriched in IFN-γ-treated iPS-MPs 
from all clones (D) and untreated (E) are shown (size-filtered by 15-500). 
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TABLES 
Table E1. List of primers 
 
  
NOD2 genotyping Sequence 1 Sequence 2
NOD2 PCR AACTAAACTCTGACACAGGAAATGGTTT AGCAGGTACATATCTGTAGTGGTCTTT
NOD2 sequencing AGAGAAGCCCTTGAGGTTGAACT
qPCR for NOD2
expression Sequence 1 Sequence 2
NOD2 CTCCATGGCTAAGCTCCTTG CACACTGCCAATGTTGTTCC
GAPDH ACCACAGTCCATGCCATCAC TCCACCACCCTGTTGCTGTA
qPCR for ChIP Sequence 1 Sequence 2
IL-6 CCCTCACCCTCCAACAAAGATTTAT GCCTCAGACATCTCCAGTCCTATAT
IL-8 AGCACTCCATAAGGCACAAAC AAATCAGGAAGGCTGCCAAG
qPCR for PSC-associated
genes
NANOG
OCT3/4
GAPDH
Hs02387400_g1 NANOG FAM-MGB
Hs00999634_gH POU5F1 FAM-MGB
Hs02758991_g1 GAPDH VIC-MGB
 52 
Table E2. Characterization of the Blau iPSCs. 
TFs: Transcription Factors 
  
iPSC line Karyotype Residual plasmid
The expression of
pluripotency-
associated TFs
(Nanog, Oct4)
NOD2 mutations Reprogrammingmethods
Teratoma
formation
Blau1A Normal Checked Yes Yes Episomal Yes
Blau1B Normal Checked Yes Yes Episomal No experiment
Blau1C Normal Checked Yes Yes Episomal No experiment
Blau1D Normal Checked Yes Yes Episomal No experiment
Blau1E Normal Checked Yes Yes Episomal Yes
Blau1F Normal Checked Yes Yes Episomal No experiment
Blau2A Normal Checked Yes Yes Episomal No experiment
Blau2B Normal Checked Yes Yes Episomal Yes
Blau2C Normal Checked Yes Yes Episomal Yes
Blau2D Normal Checked Yes Yes Episomal No experiment
Blau2E Normal Checked Yes Yes Episomal No experiment
Blau2F Normal Checked Yes Yes Episomal No experiment
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Blau2-R334W untreated
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Blau2-corrected +MDP
201B7-WT +MDP
Blau2-corrected untreated
201B7-WT untreated
Enrichment in mutant iPS-MPs (+IFN-γ)
Pathway Source Gene Set Size
Enrichment score 
(ES) Normalized ES NOM p-val FDR q-val
TNFA_SIGNALING_VIA_NFKB Hallmarks 59 0.6268927 2.181903 0 0
INFLAMMATORY_RESPONSE Hallmarks 61 0.6076938 2.146192 0 0
INTERFERON_GAMMA_RESPONSE Hallmarks 79 0.57671905 2.1370423 0 0
IL6_JAK_STAT3_SIGNALING Hallmarks 38 0.6475777 2.056878 0 0
INTERFERON_ALPHA_RESPONSE Hallmarks 48 0.5802617 1.9553326 0 0.000646524
COMPLEMENT Hallmarks 71 0.48521838 1.7649386 0 0.011213092
EPITHELIAL_MESENCHYMAL_TRANSITION Hallmarks 62 0.47770473 1.7032619 0.004219409 0.017849123
UV_RESPONSE_UP Hallmarks 63 0.47359285 1.6649346 0 0.02384537
HYPOXIA Hallmarks 67 0.41895214 1.5204836 0.031460673 0.07848985
APOPTOSIS Hallmarks 61 0.41135857 1.4504402 0.02736842 0.11839297
XENOBIOTIC_METABOLISM Hallmarks 65 0.3961556 1.423434 0.05907173 0.13181272
IL2_STAT5_SIGNALING Hallmarks 73 0.3765825 1.3864235 0.034343433 0.14425212
MYOGENESIS Hallmarks 56 0.3995071 1.388091 0.06163022 0.15486416
Enrichment in mutant iPS-MPs (untreated)
Pathway Source Gene Set Size
Enrichment score 
(ES) Normalized ES NOM p-val FDR q-val
INTERFERON_ALPHA_RESPONSE Hallmarks 48 0.67600405 2.1682627 0 0
INFLAMMATORY_RESPONSE Hallmarks 61 0.61450595 2.0468786 0 0
KRAS_SIGNALING_UP Hallmarks 53 0.6118137 2.0016701 0 0.000402299
INTERFERON_GAMMA_RESPONSE Hallmarks 79 0.5622118 1.958193 0 0.000885057
IL6_JAK_STAT3_SIGNALING Hallmarks 38 0.6143019 1.8759227 0.00170068 0.003712934
COAGULATION Hallmarks 44 0.56349194 1.7755078 0.001751314 0.007551652
TNFA_SIGNALING_VIA_NFKB Hallmarks 60 0.5434472 1.7924685 0.00170068 0.008209558
COMPLEMENT Hallmarks 70 0.5060827 1.7256396 0 0.012065775
UV_RESPONSE_DN Hallmarks 40 0.5571624 1.7081132 0.003669725 0.013691406
XENOBIOTIC_METABOLISM Hallmarks 61 0.45882583 1.5303006 0.008431703 0.06402928
IL2_STAT5_SIGNALING Hallmarks 73 0.44722065 1.5390687 0.006908463 0.06633256
P53_PATHWAY Hallmarks 79 0.4134942 1.4353017 0.031948883 0.11590166
APOPTOSIS Hallmarks 61 0.42916098 1.4355613 0.02982456 0.12515032
ALLOGRAFT_REJECTION Hallmarks 59 0.40947887 1.346638 0.07093426 0.20153947
EPITHELIAL_MESENCHYMAL_TRANSITION Hallmarks 66 0.39005163 1.3293082 0.08471761 0.21287984
FATTY_ACID_METABOLISM Hallmarks 63 0.38652363 1.2953165 0.08658744 0.24567403
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Enrichment in IFN-γ-treated iPS-MPs
Pathway Source Gene Set Size
Enrichment score 
(ES) Normalized ES NOM p-val FDR q-val
INTERFERON_GAMMA_RESPONSE Hallmarks 79 0.8985477 2.751315 0 0
INTERFERON_ALPHA_RESPONSE Hallmarks 48 0.9124301 2.5905898 0 0
ALLOGRAFT_REJECTION Hallmarks 61 0.7284121 2.138216 0 0
TNFA_SIGNALING_VIA_NFKB Hallmarks 60 0.6681717 1.983052 0 0.000177778
COMPLEMENT Hallmarks 71 0.6766195 2.0574958 0 0.000213333
INFLAMMATORY_RESPONSE Hallmarks 61 0.697921 2.0632613 0 0.000266667
IL2_STAT5_SIGNALING Hallmarks 74 0.57768124 1.7579609 0 0.004083656
IL6_JAK_STAT3_SIGNALING Hallmarks 38 0.60903025 1.6721328 0 0.013701916
KRAS_SIGNALING_UP Hallmarks 55 0.525633 1.5198836 0.018099548 0.06514271
COAGULATION Hallmarks 46 0.5265207 1.500479 0.023696683 0.069932535
XENOBIOTIC_METABOLISM Hallmarks 65 0.48838064 1.4638299 0.01627219 0.088731654
KRAS_SIGNALING_DN Hallmarks 47 0.4963301 1.4268609 0.040310077 0.112303644
REACTIVE_OXIGEN_SPECIES_PATHWAY Hallmarks 19 0.5805577 1.3578522 0.11655405 0.17184703
Enrichment in untreated iPS-MPs
Pathway Source Gene Set Size
Enrichment score 
(ES) Normalized ES NOM p-val FDR q-val
E2F_TARGETS Hallmarks 101 -0.65001583 -2.354242 0 0
G2M_CHECKPOINT Hallmarks 96 -0.53064686 -1.8772541 0 0.003215106
MYC_TARGETS_V2 Hallmarks 26 -0.6124071 -1.71684 0.002506266 0.015320513
MITOTIC_SPINDLE Hallmarks 81 -0.43526733 -1.5149827 0.015576324 0.07948423
EPITHELIAL_MESENCHYMAL_TRANSITION Hallmarks 66 -0.43605107 -1.4756967 0.008403362 0.0863585
MYC_TARGETS_V1 Hallmarks 84 -0.3805695 -1.3113842 0.07467532 0.17553833
APICAL_JUNCTION Hallmarks 58 -0.39882156 -1.3230538 0.086053416 0.18489356
UV_RESPONSE_DN Hallmarks 40 -0.4236093 -1.2739689 0.14323607 0.19474271
GLYCOLYSIS Hallmarks 78 -0.39538333 -1.3299203 0.039215688 0.20565085
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